Only 7 percent of hospitals meet Leapfrog medication error prevention (CPOE) standards and few hospitals are  meeting mortality standards, according to the 2008 Leapfrog Hospital Survey, released Wednesday.

…

Other highlights of the 2008 hospital survey include:

• Low percentages of reporting hospitals are meeting volume and risk-adjusted mortality standards or adhering to nationally endorsed process measures for eight high-risk procedures, where following nationally endorsed and evidence-based guidelines is known to save lives:
  • 43 percent for heart bypass surgery;
  • 35 percent for heart angioplasty;
  • 32 percent for high-risk deliveries;
  • 23 percent for pancreatic resections;
  • 16 percent for bariatric surgery;
  • 15 percent for esophagectomy;
  • 7 percent for aortic valve replacement; and
  • 5 percent for aortic abdominal aneurysm repair.
• Sixty-five percent of participating hospitals do not have all recommended policies in place to prevent common hospital-acquired infections (HAIs).

Full article:  Most hospitals fall short on safety measures, Leapfrog survey shows

>>April 15th

The Press Association:  Breakthrough in superbug fight

Queen’s University Belfast may have made a breakthrough discovery in superbug’s natural resistance to disinfectants.

Many types of bacteria, such as MRSA, exist in colonies that adhere to the surfaces of materials.

The colonies often form coatings, known as biofilms, that protect them from antiseptics, disinfectants, and antibiotics.

Assistant director at Quill [Queen's University Ionic Liquid Laboratories (Quill)] Mr Earle added: “We have shown that, when pitted against the ionic liquids (salts) we developed and tested, biofilms offer little or no protection to MRSA, or to seven other infectious micro-organisms.”

>>April 16th

‘We’ve cut MRSA rate to zero’ – city hospital

A hospital in Ireland adopts Scandanavian anti-HAI, which proves dramatically effective.

The Mater Private Hospital in Dublin has cut its MRSA infection rate to zero due to the introduction of a new Scandinavian hygienic programme.

The ‘Search and Destroy’ scheme has been implemented over the past few years and there were zero recorded MRSA-related infections in the hospital in 2008.

…

Ms Higgins said that MRSA needs to be tackled by a combination of actions and that this particular technique involves swabbing certain high-risk patients for the infection at the time of admission to hospital.

A representative said that patients with MRSA, as well as those who have a high risk of infection, are isolated from other patients

Superbug payments under spotlight

Investigative news program highlights the millions of pounds paid out in the UK to claims involving HAI:

Millions of pounds were paid out in patient compensation claims involving allegations about hospital superbugs in the past five years, Channel 4 News online has found.

The payout figures, obtained from the NHS under freedom of information (FoI) laws, reveal the number of settlements made to victims when MRSA or C. diff allegations were included as part of their overall claim for compensation for injury.

…

According to the figures, obtained from the NHS Litigation Authority (NHSLA), which defends compensation claims for health authorities, £4,000,462 was paid out to 44 claimants who included MRSA allegations as part of their overall claim in 2005, £1,964,617 to 32 claimants in 2006, £4,964,679 to 63 claimants in 2007, and £1,493,410 to 27 claimants last year.

In a study funded by NIH, Harvard Medical School, and the Irish Health Research Board, researchers have found a method to accurately predict which patients will experience a recurrence of C.difficile infection:

The method correctly identified 77.3% of patients who had recurrent infection in a derivation cohort studied in 1998, according to Ciarán P. Kelly, M.D., of Harvard Medical School, and colleagues.

…

C. difficile has become the leading cause of hospital-acquired infectious diarrhea. It affects millions of patients a year. Multiple recurrences are common, despite successful treatment of the initial episode

“This rule is valuable in clinical practice as it defines a high-risk population in whom awareness of the risk can facilitate more prompt recognition, diagnosis, and treatment of recurrent C. difficile,” Dr. Kelly said in a statement.

The rule combines three variables: age, disease severity, and antibiotic use.

Full article:  Clinical Rule Predicts C. Diff Recurrrence

>>Mar 10/09

Support Services Crucial to Infection Control, Study Says
CUPE says control of HAI is “much more complex than people just washing their hands”:

The research paper draws from reports in countries including Canada, Scotland and the United Kingdom, which note that clinical studies and audits have linked HAI outbreaks with understaffing, increased workload, high turnover and inadequate training.

Charlottetown medical unit reopens after superbug causes lockdown
A Charlottetown hospital, which recently stated an outbreak of MRSA and VRE was over, just re-opened after lockdown to control another superbug problem.

Part of Charlottetown’s Queen Elizabeth Hospital was locked down Monday afternoon and night, and has since reopened after a patient tested positive for a superbug.

Hospital officials are still trying to determine the source of the bacteria.

>>Mar 11/09

How contractors are battling infection during hospital construction
Building Design & Construction looks at how hospital infection control can be considered at the earliest stage of construction or renovation.

Every year, about 90,000 patients in U.S. hospitals contract nosocomial infections — they get sick (or sicker) from something they caught in the hospital. Two or three thousand of them die as a result.

Building Teams are helping to attack this problem by taking steps to control the spread of infection sources during construction of new facilities or additions, or during renovation of existing hospitals.

>>Mar 12/09

Kenta Secures $10M to Advance Antibodies against Nosocomial Infections
Kenta Biotech has raised $10m in private financing to cover the “ongoing development of two antibodies targeting aggressive bacteria that cause nosocomial infections.”